Biopharma Innovation Needs to Harness Lessons Learned from Covid-19
An article on the Stat website noted that new technologies and algorithms are making it possible to invest in areas where the best results can be obtained and simultaneously address longstanding imperatives of patient privacy and confidentiality. Individuals and companies in the biopharma ecosystem need to recognize where they are strong, but also understand where collaboration may be critical as another company may have stronger capabilities in a specific area. This is essential to moving beyond the current siloed frameworks. By adopting an open innovation and entrepreneurial ecosystem, companies can more rapidly build data pools, leverage insights from analytics, and adopt new tools.